| License: Creative Commons Attribution 4.0 PDF - Published Version (671kB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-521265
- DOI to cite this document:
- 10.5283/epub.52126
Abstract
Neoadjuvant chemotherapy (NACT) is frequently used in patients with early breast cancer. Randomized controlled trials have demonstrated similar survival after NACT or adjuvant chemotherapy (ACT). However, certain subtypes may benefit more when NACT contains regimes leading to high rates of pathologic complete response (pCR) rates. In this study we analyzed data using the OncoBox research from ...

Owner only: item control page